鲁丁改善了糖尿病动物血管和洞穴体上的基和内皮功能障碍
Rafael de Morais Campos1, Lucília Maria Abreu Lessa Leite Lima1, Ariana Gomes da Silva1
1Superior Institute of Biomedical Sciences, Ceará State University, Fortaleza, Ceará, Brazil.
Research in veterinary science
|July 5, 2023
概括
鲁丁是一种强大的抗氧化剂,可以改善糖尿病动物模型中的内皮功能障碍和性神经病变. 这表明,素可能是预防糖尿病相关血管并发症的有价值的辅助治疗方法.
科学领域:
- 生物医学科学 生物医学科学
- 药理学 药理学是指药理学的学科.
- 糖尿病学 糖尿病学
背景情况:
- 内皮功能障碍是早期糖尿病并发症,与微血管和宏血管病有关.
- 氧化压力在糖尿病中显著导致尼特尔基和内皮功能障碍.
- 糖尿病自主神经病变影响超过70%的患者.
研究的目的:
- 研究一种强有力的抗氧化剂 - - 路丁在改善糖尿病动物模型中的和内皮功能障碍方面的潜力.
- 为了评估 rutin 在初级和二级治疗方案中的有效性.
主要方法:
- 实验对老鼠大动脉环和中腔动脉床,子大动脉环和洞体 (RbCC) 从euglycemic和alloxan-diabetic动物进行了实验.
- 评估了由乙胆诱导的内皮依赖和由酸诱导的内皮独立放松.
- 在RbCC中评估电场刺激 (EFS) 诱导的放松.
主要成果:
- 与对照动物相比,糖尿病动物的内皮依赖放松减少了40%,神经元放松减少了50%.
- 在糖尿病人组织中,用鲁丁进行前期治疗显著恢复了内皮和神经元的放松.
- 鲁丁在改善内皮功能障碍和性神经病变方面表现出有效性.
结论:
- 在实验糖尿病模型中,常规有效地改善了内皮功能障碍和性神经病变.
- 鲁作为辅助治疗的主要化合物在预防或管理糖尿病相关的血管并发症方面表现有前途.
相关概念视频
Nitric Oxide Signaling Pathway
5.1K
Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure...
5.1K
Antihypertensive Drugs: Vasodilators
576
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
576
Antianginal Drugs: Nitrates and β-Blockers
656
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
656
Coronary Artery Disease II: Pathophysiology
14
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
14
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
194
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
194
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
467
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
467


